New combinations and immunotherapies for melanoma: latest evidence and clinical utility
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New combinations and immunotherapies for melanoma: latest evidence and clinical utility
Authors
Keywords
-
Journal
Therapeutic Advances in Medical Oncology
Volume 5, Issue 5, Pages 278-285
Publisher
SAGE Publications
Online
2013-08-02
DOI
10.1177/1758834013499637
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436).
- (2017) J. R. Infante et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells
- (2013) Kaitlyn Le et al. Pigment Cell & Melanoma Research
- Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California
- (2013) R. S. Lo et al. Pigment Cell & Melanoma Research
- Melanoma and other skin tumors
- (2012) J. Sosman et al. ANNALS OF ONCOLOGY
- Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection ofBRAFV600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant Melanoma
- (2012) Steven Anderson et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review and Practice Guideline
- (2012) T. Petrella et al. CLINICAL ONCOLOGY
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma
- (2012) Harkanwal Halait et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- BRAF inhibitor activity in V600R metastatic melanoma
- (2012) Oliver Klein et al. EUROPEAN JOURNAL OF CANCER
- Abstracts
- (2012) JOURNAL OF MOLECULAR DIAGNOSTICS
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm
- (2012) Muhammad Khattak et al. Therapeutic Advances in Medical Oncology
- Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project
- (2011) C. A. Gonzalez et al. ANNALS OF ONCOLOGY
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis
- (2010) S. Mocellin et al. JNCI-Journal of the National Cancer Institute
- Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress
- (2010) Keith T. Flaherty Pigment Cell & Melanoma Research
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now